首页> 外国专利> 8-SUBSTITUTED XANTHINES AS SELECTIVE ADENOSINE RECEPTOR AGENTS

8-SUBSTITUTED XANTHINES AS SELECTIVE ADENOSINE RECEPTOR AGENTS

机译:8位取代的黄嘌呤作为腺嘌呤选择性受体的代理

摘要

Xanthine derivatives having general structure (I) including the (R) and (S) enantiomers and racemic mixtures thereof, and thepharmaceutically acceptable salts thereof, wherein R1 and R2 are each independently (C1-C4)lower alkyl or (C2-C4)lower alkenyl Z is (II)or (III) or (IV) wherein R3 is hydrogen, (C1-C3)lower alkyl, nitro, amino. hydroxy, fluoro, bromo or chloro, R4 is (C1-C4)lower alkyl and nis 1 or 2 which act selectively at adenosine receptors and which are in general as adenosine antagonists are disclosed. From in vitro studiesit is known that specific physiological effects can be distinguished as a result of this selectivity and that adenosine receptor activity in vitrocorrelates with adenosine receptor activity in vivo. Pharmaceutical preparations of the subject compounds can be prepared on the basis ofthe selective binding activity of the compounds disclosed herein which will enhance certain physiological effects while minimizing others,such as decreasing blood pressure without decreasing heart rate.
机译:具有通式(I)的黄嘌呤衍生物,包括(R)和(S)对映异构体及其外消旋混合物,以及其药学上可接受的盐,其中R 1和R 2各自独立地为(C1-C4)低级烷基或(C2-C4)低级烯基Z为(II)或(III)或(IV),其中R 3为氢,(C 1 -C 3)低级烷基,硝基,氨基。羟基,氟,溴或氯,R4是(C1-C4)低级烷基,n公开了选择性地作用于腺苷受体的R 1或R 2,它们通常作为腺苷拮抗剂。来自体外研究众所周知,由于这种选择性以及体外的腺苷受体活性,可以区分出特定的生理作用。与体内腺苷受体活性相关。主题化合物的药物制剂可以在以下基础上制备:本文公开的化合物的选择性结合活性,将增强某些生理作用,同时最大限度地减少其他生理作用,例如在不降低心率的情况下降低血压。

著录项

  • 公开/公告号CA2159989C

    专利类型

  • 公开/公告日1998-11-24

    原文格式PDF

  • 申请/专利权人

    申请/专利号CA2159989

  • 发明设计人 LENTZ NELSEN L.;PEET NORTON P.;

    申请日1994-04-13

  • 分类号C07D473/06;A61K31/52;

  • 国家 CA

  • 入库时间 2022-08-22 02:24:09

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号